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Abstract: Osteoporosis in men is an increasingly recognized problem with associated fracture 
morbidity and mortality. Treatment is limited, with the bisphosphonates being the mainstay of 
therapy. Risedronate has demonstrated fracture efﬁ  cacy in women and efﬁ  cacy has been recently 
been investigated in men. In men, risedronate either maintains or increases bone mineral density. 
In placebo controlled trials it has been shown to be safe and effective in preventing fractures.
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Osteoporosis in men
Osteoporosis is increasingly recognized in men as a condition that is associated 
with signiﬁ  cant morbidity and mortality. Data from the third National Health and 
Nutrition Examination Survey (NHANES III) indicate that 3%–6% of men in the US 
have osteoporosis and 28%–47% have osteopenia when using male cut-offs for bone 
mineral density (BMD) (Looker et al 1997). In a population-based sample Melton 
et al compared osteoporosis in men with women (Melton et al 1998). By World 
Health Organization criteria, the age-adjusted prevalence of osteoporosis at the hip, 
spine, or wrist was 35% among women 50 years of age or older. A similar approach 
produced an osteoporosis prevalence rate in men 50 years of age and older of 19%. 
They showed that bone density predicts fracture risk in men as it does in women, and 
the prevalence of osteoporosis in men, using sex-speciﬁ  c normal values, is substantial. 
They concluded that there was a need for better prevention and treatment strategies 
for men (Melton et al 1998).
There are several differences in the clinical presentation of osteoporosis between 
men and women (Poor et al 1995a; Vanderschueren et al 2000; Diamond 2005). Men 
achieve approximately 1% greater peak bone mass than women at the spine and 5% at 
the femoral neck (Looker et al 1997; Tenenhouse et al 2000). Although the incidence 
of osteoporosis-related fractures is much less in men, osteoporotic fractures are 
associated with greater morbidity and mortality in men compared with women (Jiang 
et al 2005). Among men and women >50 years of age, the incidence of spinal fractures 
was estimated at 5% and 16% and that of hip fractures at 6% and 18%, respectively 
(Diamond 2005). Men with hip fractures have greater mortality (Poor et al 1995b; 
Jiang et al 2005; Hawkes et al 2006) and at least in one study were twice likely to die 
compared with women with hip fractures (Poor et al 1995a). Among men with hip 
fractures who survive, 80% will not regain their prefracture functional status and up 
to 50% will be institutionalized (Poor et al 1995b).
Observational data showed that men referred to tertiary care osteoporosis centers had 
higher mean baseline femoral neck and lumbar spine bone mineral densities than women, 
yet they had double the rate of prevalent vertebral fractures compared with women and triple 
the rate of multiple prevalent vertebral fractures compared with women (Sawka et al 2004). Clinical Interventions in Aging 2007:2(3) 276
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Furthermore, men were twice as likely as women to sustain 
a fracture within 2 years of starting treatment during the 
observation period. It was suggested that osteoporosis may be 
under-recognized in men until the condition is at an advanced 
stage and that a form of gender bias may exist in the recognition 
and treatment or referral for treatment of osteoporosis in men.
In male patients presenting with osteoporotic fractures, 
major causes of skeletal fragility, such as hypogonadism, 
glucocorticoid excess, primary hyperparathyroidism and 
alcohol abuse, can often be identiﬁ  ed (Vanderschueren et al 
2000). In as many as 50% of osteoporotic men, however, no 
etiology can be found (Vanderschueren et al 2000). The loss 
of skeletal integrity in aging men may be partially related to 
endocrine deﬁ  ciencies, including vitamin D, androgen, and/or 
estrogen deﬁ  ciency. While the consequences of vitamin D 
or estrogen deﬁ  ciency in women have been well established, 
the skeletal impact of these (partial) age-related deﬁ  ciencies 
in men remains to be clariﬁ  ed. As knowledge about the 
prevalence and etiology of osteoporosis in men increases, 
it will be recognized and treated in more men, in hopes of 
preventing fracture.
Risedronate
Risedronate [1-hydroxy-2-(3-pyridinyl)ethylidene 
bisphosphonic acid monosodium salt], (Cincinnati), is a 
potent pyridinyl bisphosphonate that has been shown to 
decreases the risk of vertebral and nonvertebral fractures 
in postmenopausal women with osteoporosis (Harris 
et al 1999; Reginster et al 2000; McClung et al 2001). 
Recently it has been studied in men under a variety of 
clinical circumstances (Table 1).
Primary osteoporosis
Boonen et al recently reported in abstract from, a 2-year, 
double-blind, randomized, placebo-controlled, parallel 
group, multicenter study to determine the efﬁ  cacy and safety 
of risedronate 35 mg once a week (Boonen et al 2006), 
compared with placebo in men with osteoporosis. Men 
between the ages of 36 and 84 years, inclusive, who had 
osteoporosis deﬁ  ned as either a lumbar spine T-score –2.5 
and femoral neck T-score –1 SD or a lumbar spine T-score 
–1 and femoral neck T-score –2 SD were randomized 
(2:1) to either risedronate 35 mg once a week (n = 191) or 
placebo (n = 93). All received daily supplementation of 
calcium (1000 mg) and vitamin D (400–500 IU) for 2 years. 
Efﬁ  cacy was assessed by percentage change from baseline 
in lumbar spine and total proximal femur, femoral neck, 
and femoral trochanter bone mineral density (BMD) and 
bone turnover markers (BTMs) including type I collagen 
C- telopeptide (Ctx), type I collagen N-telopeptide/creatinine 
(Ntx/cr), and bone speciﬁ  c alkaline phosphatase (BSAP). 
BMD was measured at months 6, 12, 24, and end point.
The primary endpoint showed a statistically signiﬁ  cant 
difference between risedronate and placebo groups in mean 
percent change from baseline to endpoint in lumbar spine 
BMD 4.53% (95% CI: 3.46%, 5.60%). The risedronate group 
had statistically signiﬁ  cant increases compared with placebo 
in mean percentage change from baseline for lumbar spine 
BMD at months 6, 12, and 24, total proximal femur and 
femoral trochanter BMD at months 12, 24, and endpoint, 
and femoral neck BMD at month 24 and endpoint. The mean 
percentage change values for all BTMs were statistically 
signiﬁ  cantly reduced in the risedronate group compared with 
baseline and with placebo at all time points measured. 
The two treatment groups were comparable in overall 
percentages of patients with adverse events (AEs) (73%, 
placebo, 70% risedronate), serious AEs (16% placebo, 15%, 
risedronate), moderate to severe upper GI AEs (4% placebo, 
3% risedronate) and overall musculoskeletal AEs (11% 
placebo, 12% risedronate). In this 2-year study, risedronate 
35 mg once a week was safe and effective for the treatment 
of osteoporosis in men.
Ringe et al (2006) assessed the efficacy and safety 
of risedronate in the treatment of men with primary and 
secondary osteoporosis. They conducted a single-center, open 
label, randomized, prospective 1-year study where patients 
were randomized to risedronate (risedronate 5 mg/day plus 
calcium 1000 mg/day and vitamin D 800 IU/day) or control 
groups (alfacalcidol 1 μg/day plus calcium 500 mg/day or 
vitamin D 1000 IU/day plus calcium 800 mg/day). The mean 
age in the risedronate-treated group was 55.8 years and in 
the control group 58.0 years. Prevalent vertebral fractures 
were present in 53.2% of the risedronate group and 51.3% of 
the control group. BMD measurements, x-rays of the spine, 
and patient self-assessments of back pain were performed at 
baseline and 12 months. Blinded semi-quantitative fracture 
assessment was conducted by a radiologist. A total of 316 
men with osteoporosis were enrolled in the trial (risedronate, 
n = 158; control, n = 158). At 1 year, lumbar spine BMD 
increased by 4.7% in the risedronate group versus an increase 
of 1.0% in the control group (p < 0.001). Signiﬁ  cant increases 
in BMD at the total hip and femoral neck were also observed 
with risedronate compared with the control group. Over 
1 year, 8 patients suffered new vertebral fractures (5.1%) 
in the risedronate-treated group, compared with 20 patients 
with new vertebral fractures (12.7%) in the control group, Clinical Interventions in Aging 2007:2(3) 277
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representing a 60% (p = 0.028) reduction in fractures. 
Nonvertebral fractures occurred in 10 patients (6.3%) in the 
risedronate-treated group compared with 17 patients (10.8%) 
in the control group. They concluded that daily treatment with 
risedronate for 12 months signiﬁ  cantly increased BMD at the 
lumbar spine, femoral neck, and total hip and signiﬁ  cantly 
reduced the incidence of new vertebral fractures.
Corticosteroid-induced bone loss
Limited information is available on the effect of 
bisphosphonates in men receiving corticosteroid therapy. 
Reid et al (2001) studied 184 men among the patients enrolled 
in two double-blind, placebo-controlled, 1-year studies 
with similar protocols. The studies evaluated the effects of 
risedronate in patients beginning corticosteroid treatment 
(prevention study) at a dose of at least 7.5 mg per day of 
prednisone or equivalent or continuing long-term treatment 
of corticosteroid (treatment study) at that dose. The men 
received either placebo or risedronate (2.5 mg or 5 mg) 
daily, along with calcium supplementation (500–1000 mg). 
Endpoints included differences in BMD at the lumbar spine, 
femoral neck, and femoral trochanter, assessment of vertebral 
fractures, changes in biochemical markers of bone turnover, 
and overall safety. The underlying diseases requiring 
corticosteroid treatment included rheumatoid arthritis, lung 
disease, polymyositis, polymyalgia rheumatica, temporal 
arteritis, and vasculitis. A total of 184 male patients received 
at least one dose of study drug (ITT population). The baseline 
Table 1 Summary of randomized controlled trials of risedronate for the treatment of male osteoporosis
Condition  Design  n  RIS dose   BMD   BMD   Vert   Hip
      (mg)  LS (%)  FN (%)  fracture  fracture
Primary OP (Boonen 2006)  RCT  191  35 per wk   4.5  NR  NR  NR
24  months   93 Pla  NR  NR  NR  NR
Primary and Secondary OP  RCT  158  5 per day  4.7  1.8  5.1%  NR
(Ringe 2003) 12 months    158  Pla  1.0  0.2  12.7%  NR
CIOP prevention   RCT  184  2.5 or 5    0.8a 1.5a Ris  9%  NR
(Reid 2000, 2001)      perday      Pla 24%  
12 months      Pla  −3.4  −3.3 Pooled    NR
CIOP treatment        2.5 or 5   4.8a 2.1a  2.5/5 mg vs   NR
(Reid 2001; Cohen 1999)      perday      placebo 82.4%
12 months      Pla  1.2  −0.2 reduction    NR
            (p = 0.008) 
Post-stroke (Sato 2005)  RCT  140  2.5/day  2.5b NR  NR  1.4
18 months    140  Pla  −3.5b NR NR  7.1
Hyperthyroidism   RCT  14  2.5  6.07  4.41  NR  NR
(Majima 2006)     13  Pla  1.90  2.61  NR  NR
12 months
IBD (Henderson 2006)  RCT  total 61  5  2.9  3.1  NR  NR
12 months    male 25  Pla  1.04  0.1  NR  NR
Transplantation   RCT  total 34  5  5.9  1.3  NR  NR
(Tauchmanova 2003)    male 16  Pla  1.1  −4.2 NR  NR
12 months
Leprosy (Kanaji 2006)  RCT  12  2.5  4.8c NR  0.82**  NR
9  months   11 Pla  0.9c NR  1.88  NR
Stress fractures   RCT  165  30 for 2   N/A  N/A  N/A  14.5
(Milgrom 2004)      weeks then 
3 months      30 weekly
   159  Pla  N/A  N/A  N/A  13.2
aBMD change with 5 mg dose
bmetacarpal BMD
cestimate from graph
**p < 0.05
Abbreviations: BMD, bone mineral density; CIOP, corticosteroid-induced osteoporosis; IBD, inﬂ  ammatory bowel disease; NR, not reported; OP, osteoporosis; Pla, placebo; 
RIS, risedronate; RCT, randomized controlled trial.Clinical Interventions in Aging 2007:2(3) 278
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characteristics of the 184 enrolled patients were similar 
between treatment groups. At baseline, the mean lumbar 
spine BMD was similar in the risedronate and placebo groups. 
The mean daily corticosteroid dose prior to enrollment was 
19.4 mg (SD, 16.4) and the mean corticosteroid dose during 
the 1-year study was 14.2 mg (SD, 15.7); the corticosteroid 
doses were similar among the three treatment groups. Forty 
percent of men had prevalent (baseline) vertebral fractures; 
the prevalence was slightly higher in the risedronate 5 mg 
group (46%) than in the other groups.
In the treatment study, risedronate 5 mg signiﬁ  cantly 
(p < 0.01) increased lumbar spine BMD by 4.8% at the lumbar 
spine, 2.1% at the femoral neck, and 2.6% at the femoral 
trochanter compared with baseline values (Figure 1). In the 
prevention study, bone loss was prevented with risedronate 
5 mg; in the placebo group, BMD decreased signiﬁ  cantly 
(p < 0.01) by 3.4%, 3.3%, and 3.4% in the lumbar spine, 
femoral neck, and trochanter, respectively, at 1 year (Figure 2). 
The differences between risedronate 5 mg and placebo groups 
were signiﬁ  cant at all skeletal sites in the prevention study 
(p < 0.01) and at the lumbar spine in the treatment study 
(p < 0.001). The 2.5 mg dose also had a positive effect on 
BMD, although of a lesser magnitude than the 5 mg dose. 
When the data from the two studies were combined, the 
incidence of vertebral fractures decreased 82.4% (95% CI: 
36.6%, 95.1%) in the pooled risedronate groups compared 
with placebo (p = 0.008). Risedronate was well tolerated in 
men, with a similar incidence of upper gastrointestinal adverse 
events in the placebo and treatment groups. They concluded 
that daily treatment with risedronate increases bone density 
and decreases vertebral fracture risk within 1 year in men 
receiving corticosteroid therapy.
Other conditions
Risedronate has been studied in a number of other conditions 
including post-stroke (Sato et al 2005), hyperthyroidism 
(Majima et al 2006), inﬂ  ammatory bowel disease (Henderson 
et al 2006), transplantation (Tauchmanova et al 2003), 
leprosy (Kanaji et al 2006), and stress fractures in infantry 
recruits (Milgrom et al 2004).
Post-stroke
There is a high incidence of hip fractures in patients after 
hemiplegic stroke. Bone mineral density is decreased on 
the hemiplegic side in patients after stroke, correlating with 
the immobilization-induced bone resorption, the degree 
Figure 1 Risedronate in the treatment of corticosteroid-induced osteoporosis.
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of paralysis, and hypovitaminosis D. Sato et al (2005) 
evaluated the effectiveness of risedronate on osteoporosis 
and the risk of hip fractures in men 65 years or older after 
stroke. They conducted an 18-month, randomized, double-
blind trial of 280 male patients 65 years or older who were post-
stroke, with140 receiving a daily dose of 2.5 mg risedronate 
and the other 140 receiving placebo. The mean age in both 
groups was 76.3 years. There were no signiﬁ  cant differences 
between the placebo group and risedronate group in Barthel 
Index, degree of hemiplegia, number of fallers, type of stroke, 
BMD, or biochemical indices of bone metabolism. Although 
the values of BMD on both hemiplegic and nonhemiplegic 
sides were within the reference range compared with the 
elderly general Japanese population, BMD on the hemiplegic 
side was signiﬁ  cantly reduced compared with that of the 
nonhemiplegic side. Compared with the reference range of the 
elderly general Japanese population, both groups of patients 
had high levels of serum ionized calcium and urinary D-Pyr and 
low serum concentrations of PTH, 25-OHD, and 1,25-(OH)2D 
at baseline. Serum 25-OHD was outside of the reference range 
in both groups: 114.6 ± 21.7 ng/mL (45.9 ± 8.7 nmol/L) in the 
placebo group and 114.6 ± 16.7 ng/mL (45.9 ± 6.7 nmol/L) in 
the risedronate group.
During the study, a total of 269 falls occurred in the former 
group and 278 in the latter group, or 4.2 falls per patient per 
year for both groups. In the risedronate group, 28 (20%) of 140 
patients fell at least once, and 15 (80%) fell twice or more; in 
the placebo group, 29 (21%) of 140 patients fell at least once, 
and 15 (79%) fell twice or more. The number of falls among 
fallers ranged from 1 to 12 in both groups.
Ten patients sustained hip fractures in the placebo group, 
and 2 hip fractures occurred in the risedronate group. The 
relative risk of a hip fracture was reduced with risedronate to 
0.19 (95% CI: 0.04–0.89). Bone mineral density increased by 
2.5% in the risedronate group and decreased by 3.5% in the 
placebo group (p < 0.001). Urinary deoxypyridinoline, a bone 
resorption marker, decreased by 58.7% in the risedronate 
group and by 37.2% in the placebo group. They concluded 
that treatment with risedronate increases bone mineral density 
and reduces hip fractures in elderly men who are post-stroke 
(Sato et al 2005).
Hyperthyroidism
It has been well established that hyperthyroidism leads 
to diminished BMD, and that a previous history of 
hyperthyroidism remains a risk factor for fractures. However, 
Figure 2 Risedronate in the prevention of corticosteroid-induced osteoporosis.
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little is known about how to manage the reduction in BMD 
caused by hyperthyroidism. This study evaluated the efﬁ  cacy 
of risedronate for the treatment of osteoporosis/osteopenia 
in patients with Graves’ disease (Majima et al 2006). Of 
34 Japanese male patients with newly diagnosed Graves’ 
disease, 27 with osteoporosis/osteopenia were included in 
this study. They were randomly divided into two groups by 
therapeutic regimen. Fourteen patients were treated with 
an antithyroid drug and risedronate and the control group 
consisted of 13 patients treated with the same antithyroid drug 
only. The mean age and BMI was 43.6 years and 22.86 in the 
risedronate group and 45.5 years and 22.34 respectively in 
the control group. BMD at the lumber spine, femoral neck, 
and distal radius were measured at baseline, and at 6 and 12 
months after the trial. Bone-speciﬁ  c alkaline phosphatase 
and urinary N-terminal telopeptide of type I collagen 
normalized by creatinine were signiﬁ  cantly more reduced in 
the risedronate treated group than in the control group after 
both 6 and 12 months. The percentage increases in BMD at 
the lumbar spine femoral neck and distal radius at 1 year were 
6.6%, 4.2%, and 2.4% respectively for risedronate and were 
greater than in the control group. These beneﬁ  cial effects of 
risedronate for patients with osteoporosis/osteopenia caused 
by Graves’disease may reduce risk of future fractures. They 
concluded that risedronate should be considered for the 
treatment of decreased bone mass associated with Graves’ 
disease.
Inﬂ  ammatory bowel disease
Low bone density and fractures are common in patients with 
inﬂ  ammatory bowel disease (IBD). Henderson et al (2006) 
conducted a study to determine whether risedronate is safe 
and effective in preserving bone mass compared with calcium 
alone in IBD patients with low bone mass. They enrolled 61 
ambulatory patients, 25 of whom were males, with Crohn’s 
disease (n = 31) or ulcerative colitis (n = 30) and low bone 
density in a double-blind placebo-controlled trial. Patients 
were randomized to 12 months of therapy with risedronate 
5 mg or placebo. All received a 600 mg calcium supplement. 
Bone density using dual energy x-ray absorptiometry was 
performed at baseline and at 12 months. Disease activity, use 
of corticosteroid, and adverse events were noted. Forty-eight 
patients completed the trial. Compared with the placebo 
group, risedronate resulted in a 2.0% (95% CI: 0.02–3.97) 
and 1.9% (95% CI: 0.21–3.62) improvement in bone density 
at the spine and hip, respectively. IBD diagnosis, gender, 
therapy, and disease status had no effect on the results. 
There were no signiﬁ  cant differences in the adverse events. 
They concluded that risedronate improved bone density at 
the spine and hip in patients with either Crohn’s disease or 
ulcerative colitis and low bone mass. These data suggest that 
risedronate is a safe and effective therapy to improve bone 
mass in these patients (Henderson et al 2006).
Transplantation
In this prospective randomized study risedronate was 
evaluated in patients who had undergone allogeneic stem 
cell transplant (SCT) for hematological malignancies 
(Tauchmanova et al 2003). Thirty-four patients (18 females, 
16 males, age 32 ± 10 years) with BMD T-score –1.5 SD 
at least 6 months after SCT were treated with calcium 
1 g/day and vitamin D 800 IU/day and randomized to 
receive (n = 17) or not receive (n = 17) oral risedronate 
5 mg/day. The duration of treatment was 12 months. 
After 12 months, lumbar BMD increased (5.9 ± 1.7%, 
p < 0.05), compared with baseline in risedronate-treated 
patients and increased slightly (+1.1 ± 1.4%) in the 
placebo group. They concluded that treatment with 
risedronate for 12 months increased BMD significantly 
at the lumbar spine and prevented further bone loss at 
the femoral neck in long-term survivors after allogeneic 
stem cell transplantation.
Leprosy
Kanaji et al (2006) evaluated the therapeutic effect of 
risedronate in male osteoporotic patients with leprosy. 
Twenty-three male patients with leprosy, 63–87 years of 
age, were randomly divided into two groups, risedronate, 
2.5 mg/day or placebo. The BMD of the lumbar spine 
(L2–L4) was measured by dual-energy X-ray absorptiometry 
(DXA), and urinary N-telopeptide cross-links  (NTX) 
were assessed at baseline, 6 months, and 12 months 
after treatment. There were no signiﬁ  cant differences in 
Figure 3 Vertebral fracture incidence.
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age, body mass index, BMD, or urinary NTX levels at 
baseline between the two groups. They showed that oral 
administration of risedronate prevented vertebral fractures. 
There were a mean of 0.82 new vertebral fractures per 
patient during the 12 months’ treatment in the risedronate 
group and 1.88 per patient in the placebo group. The 
number of incident vertebral fractures per patient in the 
risedronate group was signiﬁ  cantly lower than those in 
the placebo group (p < 0.05), suggesting that risedronate 
treatment prevented incident vertebral fractures. Increased 
lumbar BMD and signiﬁ  cant reductions of bone turnover 
as measured by urinary NTX levels were seen with 
risedronate compared with placebo. These ﬁ  ndings suggest 
that oral administration of risedronate contributes to the 
prevention of vertebral fractures by suppressing bone 
resorption and increasing in lumbar BMD in the elderly 
male patients with leprosy.
Stress fractures
A randomized, double-blind, placebo controlled trial of 324 
new infantry recruits known to be at high risk for stress 
fracture was conducted (Milgrom et al 2004). Recruits were 
given a loading dose of 30 mg of risedronate or placebo 
daily for 10 doses during the ﬁ  rst 2 weeks of basic training 
and then a once a week maintenance dose for the following 
12 weeks. Recruits were monitored by biweekly orthopedic 
examinations during 15 weeks of basic training for stress 
fractures. Bone scans for suspected tibial and femoral stress 
fractures and radiographs for suspected metatarsal stress 
fractures were used to verify stress fracture occurrence. 
No statistically signiﬁ  cant difference in the tibial, femoral, 
metatarsal, or total stress fracture incidence between the 
treatment group and the placebo group was seen and it was 
concluded that prophylactic treatment with risedronate in a 
training population at high risk for stress fracture using a 
maintenance dosage for the treatment of osteoporosis does 
not lower stress fracture risk.
Summary
Osteoporosis in men is a signiﬁ  cant cause of morbidity and 
mortality. Risedronate is effective in increasing BMD in 
primary and corticosteroid-induced osteoporosis in men 
and more importantly the prevention of vertebral fractures 
within the ﬁ  rst year of therapy in corticosteroid-treated men. 
Risedronate is also effective in the prevention of hip fractures 
post stroke and vertebral fractures in those with leprosy. 
Risedronate maintained BMD in those with Graves’ disease, 
inﬂ  ammatory bowel disease, cystic fbrosis and transplanta-
tion. Risedronate was ineffective in the prevention of stress 
fractures in infantry recruits.
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